JP2022025713A - Oral composition for alleviating or suppressing ultraviolet exposure-induced skin disorders - Google Patents

Abstract

To provide a composition that is effective in alleviating or suppressing ultraviolet exposure-induced skin disorders.SOLUTION: An oral composition for alleviating or suppressing ultraviolet exposure-induced skin disorders contains rice extract.SELECTED DRAWING: Figure 1

Description

The present invention relates to an oral composition containing a rice extract, which has an excellent alleviating and suppressing effect on skin disorders induced by exposure to ultraviolet rays.

As a means for suppressing or reducing skin damage caused by ultraviolet rays, many external skin preparations such as sunscreens containing an ultraviolet scattering agent or an ultraviolet absorbing agent have been proposed. Since the skin condition is also affected by oral ingestion such as meals, it is considered important to prevent it with foods that can be safely ingested for a long time. Development is being attempted. For example, oral ingestion of a composition containing methyl hesperidin has an effect of suppressing wrinkles and deterioration of keratin function due to exposure to ultraviolet rays (Patent Document 1), and oral ingestion of a composition containing taurine. It is known that there is an effect of improving wrinkles by ultraviolet rays (Patent Document 2). However, the effects of the compositions developed so far are not always sufficient, and there is a demand for the development of a new oral composition for reducing or suppressing skin disorders induced by exposure to ultraviolet rays, which is excellent in safety.

On the other hand, the rice extract is known to have an anti-fatigue effect (Patent Document 3), but the effect on skin disorders induced by ultraviolet exposure is not known.

Japanese Unexamined Patent Publication No. 2016-104806 Japanese Unexamined Patent Publication No. 2017-025097 Japanese Unexamined Patent Publication No. 2007-238081

An object of the present invention is to provide an oral composition having an excellent action of reducing and suppressing skin disorders induced by exposure to ultraviolet rays.

The applicant has made extensive studies to solve the above problems, and surprisingly, the inclusion of rice extract has an excellent oral effect of reducing and suppressing skin disorders induced by ultraviolet exposure. It has been found that the composition can be obtained. The present invention is a completed invention based on such findings.

The outline of the present invention is as follows.

[1] An oral composition for reducing or suppressing skin disorders induced by exposure to ultraviolet rays, which comprises a rice extract.
[2] An oral composition for reducing or suppressing erythema of the skin induced by exposure to ultraviolet rays, which comprises a rice extract.
[3] An oral composition for suppressing the expression of interleukin-1β, interleukin-6, or cyclooxygenase-2, which are genes related to erythema induction induced by ultraviolet exposure, which contain a rice extract.
[4] The composition according to any one of [1] to [3], wherein the rice extract contains ceramide.
[5] The composition according to [4], wherein the ceramide is glucosyl ceramide.
[6] The composition according to [5], wherein the glucosylceramide is a glucosylceramide represented by the following general formula (1).

The oral composition of the present invention is interleukin-1β (hereinafter, also referred to as “IL-1β”) and interleukin-6 (hereinafter, also referred to as “IL-6”), which are genes related to erythema induction induced by exposure to ultraviolet rays. ) Or, since it effectively suppresses the expression of cyclooxygenase-2 (hereinafter, also referred to as "COX-2"), it is excellent in reducing or suppressing erythema of the skin induced by ultraviolet exposure, and is excellent in reducing or suppressing erythema of the skin. It exerts an excellent alleviating or suppressing effect on induced skin disorders.

FIG. 1 is a diagram showing the expression levels of the erythema induction-related gene IL-1β in Examples 1 and Comparative Examples 1 and 2. FIG. 2 is a diagram showing the expression levels of the erythema induction-related gene IL-6 in Examples 1 and Comparative Examples 1 and 2. FIG. 3 is a diagram showing the expression level of the erythema induction-related gene COX-2 in Examples 1 and Comparative Examples 1 and 2.

Hereinafter, the present invention will be described in detail. The present invention is not limited to the following embodiments.

The present invention contains rice extract as an essential ingredient. As used herein, the term "rice" means seeds and seeds of the genus Oryza. The rice used in the present invention is not particularly limited as long as it belongs to the genus Oryza, but rice (Oryza sativa) is preferable from the viewpoint of reducing or suppressing skin disorders induced by ultraviolet exposure. The variety and type are not limited, and japonica, indica rice, glutinous rice, glutinous rice and the like can be used. Linne (Gramineae)) is preferred. Further, in the present invention, raw or dried rice can be used.

The processing form of rice used in the present invention is not particularly limited, and examples thereof include white rice, brown rice, and rice bran. In the present invention, brown rice and rice bran are preferable, and rice bran is more preferable, from the viewpoint of reducing or suppressing skin disorders induced by exposure to ultraviolet rays.

The extraction method of the rice extract is not particularly limited, and can be appropriately selected depending on the purpose. Examples of the extraction method include a method of adding an extraction solvent usually used by those skilled in the art such as ethanol, water, and hydrous ethanol, and heating the mixture as necessary for extraction. In the present invention, those extracted with ethanol are preferable from the viewpoint of reducing or suppressing skin disorders induced by exposure to ultraviolet rays.

The content of the rice extract blended in the composition of the present invention is not particularly limited, and the content can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. For example, when the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.001 to 80% by mass is preferable, and 0.01 to 50% is preferable. The mass% is more preferable, and 0.1 to 30% by mass is particularly preferable. Further, for example, when the composition of the present invention is a liquid agent (liquid, gel, jelly, paste, etc.), 0.0001 to 30% by mass is preferable, and 0.001 to 20% by mass is more preferable. , 0.01-10% by mass is particularly preferable.

The rice extract used in the present invention preferably contains ceramide. Ceramide is a general term for a group of compounds in which sphingosine and fatty acids are amide-bonded. As used herein, ceramide means glycosphingolipid or glycosphingolipid, which is a compound in which a sugar is glycosidically bonded to sphingolipid, or a mixture thereof.

The type of ceramide contained in the rice extract is not limited, but from the viewpoint of reducing or suppressing skin disorders induced by exposure to ultraviolet rays, glycosphingolipid is preferable, and glucosylceramide, which is a kind of glycosphingolipid, is used. Is more preferable, and glucosylceramide represented by the following general formula (1) is particularly preferable.

The content of ceramide in the rice extract used in the present invention is not particularly limited, but is preferably 1 to 80% by mass, more preferably 4 to 50% by mass, and particularly preferably 8 to 15% by mass.
In addition, the amount of ceramide in the composition of the present invention can be analyzed by liquid chromatography. For example, it can be measured by a high performance liquid chromatograph (HPLC-ELSD) equipped with a light scattering detector, and the analysis column is an Inertsil Sil 100-5 (4.6 × 150 mm) manufactured by GL Sciences Co., Ltd., which is a mobile phase. As a liquid medium, chloroform (mobile phase A) and a 95% by volume methanol solution (mobile phase B) are used, and the column temperature can be 35 ° C. and the flow rate can be 1 mL / min. The gradient conditions can be as follows.

The content of ceramide in the composition of the present invention is not particularly limited, and the content thereof can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. For example, when the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.001 to 50% by mass is preferable, and 0.01 to 40% is preferable. The mass% is more preferable, and 0.1 to 30% by mass is particularly preferable. Further, for example, when the composition of the present invention is a liquid agent (liquid, gel, jelly, paste, etc.), 0.0001 to 30% by mass is preferable, and 0.001 to 20% by mass is more preferable. , 0.01-10% by mass is particularly preferable.

The daily intake of the oral composition of the present invention is not particularly limited, and can be appropriately set according to the mode of use, the content of use by the user, and the like. For example, when the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), it is preferably 2 to 2000 mg / kg based on the weight of the user. It is more preferably 4 to 1000 mg / kg, and particularly preferably 30 to 400 mg / kg from the viewpoint of reducing or suppressing skin disorders induced by ultraviolet exposure. Further, for example, when the composition of the present invention is a liquid agent (liquid, gel, jelly, paste, etc.), it is preferably 100 to 40,000 mg / kg based on the weight of the user, more preferably. Is 300 to 30,000 mg / kg, and is particularly preferably 500 to 20,000 mg / kg from the viewpoint of reducing or suppressing skin disorders induced by ultraviolet exposure.

Similarly, the single intake of the composition of the present invention is not particularly limited. For example, when the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), it is preferably 1 to 2000 mg / kg based on the weight of the user. It is more preferably 2.5 to 1000 mg / kg, and particularly preferably 10 to 400 mg / kg from the viewpoint of reducing or suppressing skin disorders induced by ultraviolet exposure. Further, for example, when the composition of the present invention is a liquid agent (liquid, gel, jelly, paste, etc.), it is preferably 50 to 40,000 mg / kg based on the weight of the user, more preferably. Is 100 to 30,000 mg / kg, and is particularly preferably 300 to 20,000 mg / kg from the viewpoint of reducing or suppressing skin disorders induced by ultraviolet exposure.

The daily intake of the composition of the present invention is not particularly limited, and for example, the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.). In some cases, it is preferably 0.2 to 50 g, more preferably 0.4 to 25 g, and particularly preferably 3 to 10 g from the viewpoint of reducing or suppressing skin disorders induced by ultraviolet exposure. Further, for example, when the composition of the present invention is a liquid (liquid, gel, jelly, paste, etc.), it is preferably 10 to 1000 g, more preferably 30 to 750 g, and the skin induced by ultraviolet rays. From the viewpoint of reducing or suppressing the disorder, the amount can be particularly preferably 50 to 500 g.

The single intake of the composition of the present invention is preferably, for example, when the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.). It can be 0.1 to 50 g, more preferably 0.2 to 25 g, and particularly preferably 1 to 10 g from the viewpoint of reducing or suppressing skin disorders induced by ultraviolet exposure. Further, for example, when the sleep-improving composition of the present invention is a liquid (liquid, gel, jelly, paste, etc.), it is preferably 5 to 1000 g, more preferably 10 to 750 g, and is induced by ultraviolet exposure. From the viewpoint of reducing or suppressing the skin damage to be observed, the amount can be particularly preferably 30 to 500 g.

The composition of the present invention may contain only the rice extract, or may contain other components in addition to the rice extract. As the above-mentioned other components, for example, protein, water-soluble dietary fiber, dietary fiber such as insoluble dietary fiber, minerals, plants or processed plant products other than rice, algae, lactic acid bacteria, microorganisms such as yeast, etc. are blended. Can be done. Furthermore, if necessary, sugars such as dextrins and starches, oligosaccharides, sweeteners, acidulants, colorants, thickeners, brighteners, excipients, vitamins, nutritional supplements, and bonds, which are usually used in the food field, are used. Examples thereof include agents, lubricants, stabilizers, diluents, bulking agents, emulsifiers, food additives, seasonings and the like. The content of these other components can be appropriately selected depending on the form of the composition of the present invention and the like.

The oral composition of the present invention can be utilized in various forms for the purpose of obtaining an action of reducing or suppressing skin disorders induced by exposure to ultraviolet rays.

The composition of the present invention is not particularly limited as long as it can be distinguished from other products as a product in that it is used for reducing or suppressing skin disorders induced by exposure to ultraviolet rays, for example. Functions of reducing or suppressing skin disorders induced by ultraviolet exposure, and reducing or suppressing skin erythema induced by ultraviolet exposure in any of the main body, packaging, instructions, and advertisements of the product according to the present invention. The indication that there is is included in the scope of the present invention. For example, so-called health foods such as pharmaceuticals (including quasi-drugs), foods for specified health use, foods with nutritional function, foods with functional claims, etc. Can be mentioned. In so-called health foods, "helps protect the skin from UV rays", "suppresses the redness of the skin exposed to UV rays", "suppresses the erythema of the skin exposed to UV rays", and "the erythema of the skin caused by UV rays". It is possible to exemplify what is displayed such as "suppress".

The form of the oral composition of the present invention is not particularly limited and may be any form. For example, forms suitable for oral use, specifically powder, granules, granules, tablets, liquids, gels, pastes, capsules such as hard capsules and soft capsules, caplets, tablets, etc. Examples include gel, jelly, gummy, wafer, biscuits, cookies, cakes, chewables, syrups, sticks, etc., and various excipients, depending on the form to be used. Binders, lubricants, stabilizers, diluents, bulking agents, thickeners, gelling agents, emulsifiers, colorants, fragrances, sweeteners, additives and the like can be blended. The oral composition of the present invention is preferably in the form of granules, tablets, capsules or jellies, more preferably in the form of granules, tablets or capsules, from the viewpoint of reducing or suppressing skin disorders induced by exposure to ultraviolet rays. .. Here, the granular state refers to a composition obtained by granulating powder, and may be drunk directly or may be dissolved in a liquid such as water and drunk. Further, the gel form refers to a composition containing water and a gelling agent and having viscosity or elasticity.

The packaging form of the composition of the present invention is not particularly limited and may be appropriately selected depending on the dosage form and the like. For example, a blister pack such as PTP, strip packaging, a heat seal, an aluminum pouch, a film using plastic or a synthetic resin, etc. Examples include packaging, glass containers such as vials, and plastic containers such as ampoules.

Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples, and the present invention can take various aspects as long as the problems of the present invention can be solved. ..

<Test Evaluation of the effect of reducing or suppressing erythema on the skin induced by UV exposure>
The following tests were conducted to confirm that ingestion of the composition of the present invention exerts an effect of reducing or suppressing erythema on the skin induced by ultraviolet exposure.

[Test substance]
As a test substance, a powdered rice extract obtained by adding an excipient (dextrin) to an extract obtained by extracting rice bran with ethanol was used. The proportion of glucosylceramide in the rice extract analyzed by liquid chromatography was 10.6%. The glucosylceramide contained in the rice extract contains the compound of the general formula (1) as a main component of the ceramide. In this test, a mixed feed was prepared by blending it with a mouse feed (MF powder feed, manufactured by Oriental Yeast Co., Ltd.) at a ratio of 5% by mass as a rice extract, and allowed it to be freely ingested.

[Test animal]
After acclimatization of female hairless mice (HOS: HR-1), 9-week-old individuals in good health were selected and grouped based on their body weight values.

[Structure of test group]
The three groups in Table 1 below are used.

[Ultraviolet irradiation]
On the 7th day from the start of the test, the back of the mouse was irradiated with UVB (40 mJ / cm ² ) using an ultraviolet low-pressure mercury lamp TL / 12 series (manufactured by Philips) under isoflurane anesthesia.

[Measurement of expression level of genes related to erythema induction (IL-1β, IL-6, COX-2)]
On the 8th day after the start of the test (24 hours after UVB irradiation), dissection was performed under isoflurane anesthesia, and the back skin of the mouse was collected by biopsy trepan (manufactured by Kai Industries). RNA was extracted from the collected skin, and the expression level of erythema induction-related genes (IL-1β, IL-6, COX-2) was measured using a real-time PCR method. The gene expression level of IL-1β, IL-6 or COX-2 in each test group was corrected by the gene expression level of GAPDH as an endogenous control, and the expression level of Comparative Example 2 was set to 1.0. The relative expression level of the gene related to erythema induction was calculated. In addition, IL-1β and IL-6 are inflammatory cytokines induced by ultraviolet irradiation. Irradiation of the skin with ultraviolet rays promotes the production of these inflammatory cytokines, which causes an inflammatory reaction in the skin and causes skin disorders such as erythema. In addition, COX-2 is a prostaglandin synthase involved in inflammation, and its expression is increased by irradiation with ultraviolet rays. By promoting the production of COX-2 in the skin by ultraviolet irradiation, prostaglandins that cause inflammation increase in blood vessels, causing skin disorders such as erythema. Therefore, by evaluating the expression level of genes related to erythema induction (IL-1β, IL-6, COX-2), the effect of reducing or suppressing erythema on the skin induced by ultraviolet exposure and the skin induced by ultraviolet exposure It is possible to evaluate the mitigation or suppression effect of the disorder.

[Results (Erythema induction-related gene IL-1β expression inhibitory effect)]
The expression result of IL-1β is shown in FIG. 1 (values are average values). The expression level of IL-1β was higher in the group (Comparative Example 2) in which the test substance was not administered and UV irradiation was performed, as opposed to the group in which the test substance was not administered and UV irradiation was not performed (Comparative Example 1). From this result, it was confirmed that the expression of the erythema induction-related gene IL-1β was enhanced by ultraviolet irradiation. In addition, the group to which the rice extract was administered and irradiated with ultraviolet rays (Example 1) had an expression level of IL-1β of 65% as compared with the group to which the test substance was not administered and was irradiated with ultraviolet rays (Comparative Example 2). Reduced. From the above results, it was clarified that the composition of the present invention exerts an excellent effect on the expression inhibitory effect of the erythema induction-related gene IL-1β induced by ultraviolet exposure.

[Results (Suppression of expression of erythema induction-related gene IL-6)]
The expression result of IL-6 is shown in FIG. 2 (values are average values). The expression level of IL-6 was higher in the group (Comparative Example 2) in which the test substance was not administered and UV irradiation was performed, as opposed to the group in which the test substance was not administered and UV irradiation was not performed (Comparative Example 1). From this result, it was confirmed that the expression of the erythema induction-related gene IL-6 was enhanced by ultraviolet irradiation. In addition, the group to which the rice extract was administered and irradiated with ultraviolet rays (Example 1) had an IL-6 expression level of 47% as compared with the group to which the test substance was not administered and was irradiated with ultraviolet rays (Comparative Example 2). Reduced. From the above results, it was clarified that the composition of the present invention exerts an excellent effect on the expression inhibitory effect of the erythema induction-related gene IL-6 induced by ultraviolet exposure.

[Results (Suppression of expression of erythema induction-related gene COX-2)]
The expression result of COX-2 is shown in FIG. 3 (values are average values). The expression level of COX-2 was higher in the group to which the test substance was not administered and to which the ultraviolet irradiation was performed (Comparative Example 2) than to the group to which the test substance was not administered and was not irradiated with ultraviolet rays (Comparative Example 1). From this result, it was confirmed that the expression of the erythema induction-related gene COX-2 was enhanced by ultraviolet irradiation. In addition, the group to which the rice extract was administered and irradiated with ultraviolet rays (Example 1) had a COX-2 expression level of 31% as compared with the group to which the test substance was not administered and was irradiated with ultraviolet rays (Comparative Example 2). Reduced. From the above results, it was clarified that the composition of the present invention exerts an excellent effect on the expression inhibitory effect of the erythema induction-related gene COX-2 induced by ultraviolet exposure.

As shown in FIGS. 1 to 3, the oral ingestion of the rice extract effectively suppresses the expression of the erythema-inducing-related genes IL-1β, IL-6 or COX-2 induced by UV exposure. Therefore, the composition of the present invention has an excellent effect of reducing or suppressing erythema of the skin induced by ultraviolet exposure, and exhibits an excellent effect of reducing or suppressing skin disorders induced by ultraviolet exposure.

(Manufacturing example)
Based on the results of the examples, the production examples of the present invention are shown below.

[Production Example 1-4: Granules]
As shown in Table 2, after mixing the rice extract and other raw materials, fluidized bed granulation was performed using a granulator and filled in sachets to produce the granules described in Production Example 1-4. .. The granules were produced in 3 g per packet. The granules described in Production Example 1-4 may be ingested in 1 to 3 packets per day, may be ingested by dissolving in a solvent such as 100 ml of water, or may be ingested as it is without being dissolved. All of the granules of Production Examples 1-4 are effective in reducing or suppressing skin disorders induced by ultraviolet exposure and in reducing or suppressing erythema of the skin induced by ultraviolet exposure.

[Production Example 5-8: Tablets]
As shown in Table 3, the rice extract and other raw materials were mixed and then tableted using a rotary tableting machine to produce tablets of Production Example 5-8. The tablets were produced with a tablet diameter of 8 mmφ, a tablet thickness of 4.5 mm, a weight of 300 mg, and a hardness of 5 kgf or more. The tablets described in Production Example 5-8 may be ingested 1 to 2 tablets per day, and can be ingested together with 100 ml of water or the like. Any of the tablets of Production Example 5-8 is effective in reducing or suppressing skin disorders induced by ultraviolet exposure and in reducing or suppressing erythema of the skin induced by ultraviolet exposure.

[Production Example 9-12: Soft capsule]
As shown in Table 4, the rice extract and other raw materials were mixed and then encapsulated with a film containing gelatin and glycerin to produce a soft capsule of Production Example 9-12. The soft capsule was produced with a content liquid weight of 300 mg. The soft capsules described in Production Examples 9-12 may be ingested in 1 to 2 capsules per day, and can be ingested together with 100 ml of water or the like. Any of the soft capsules of Production Examples 9-12 is effective in reducing or suppressing skin disorders induced by ultraviolet exposure and in reducing or suppressing erythema of the skin induced by ultraviolet exposure.

[Production Example 13-16: PET Beverage]
As shown in Table 5, a liquid preparation in which rice extract and other raw materials were mixed was packed in a PET container to produce a PET beverage of Production Example 13-16. The PET beverage was produced in 500 ml per bottle. The PET beverage described in Production Examples 13-16 may be ingested once a day. Any PET beverage of Production Examples 13-16 is effective in reducing or suppressing skin disorders induced by UV exposure and in reducing or suppressing skin erythema induced by UV exposure.

[Production Example 17-20: Jelly Agent]
As shown in Table 6, the rice extract and other raw materials were mixed, and then the heated liquid agent was filled in the pouch to produce the jelly agent of Production Example 17-20. The jelly agent was produced at 200 g per piece. The jelly agent of Production Example 17-20 may be ingested once a day. Any of the jelly agents of Production Examples 17-20 is effective in reducing or suppressing skin disorders induced by ultraviolet exposure and in reducing or suppressing erythema of the skin induced by ultraviolet exposure.

The oral composition of the present invention has an action of reducing or suppressing erythema of the skin induced by ultraviolet exposure by an action of suppressing the expression of erythema induction-related genes IL-1β, IL-6 or COX-2 induced by ultraviolet exposure. In addition, it is highly industrially useful because it exerts an excellent alleviating or suppressing effect on skin disorders induced by exposure to ultraviolet rays.

Claims (2)

An oral composition for reducing or suppressing UV exposure-induced skin disorders, which comprises a rice extract. An oral composition for reducing or suppressing erythema of the skin induced by UV exposure, which comprises a rice extract.

Images